FindTrial
Sign In

KSI-301

DRUG7 trials

Sponsors

Kodiak Sciences Inc

Conditions

Diabetic Macular EdemaMacular EdemaNon-proliferative Diabetic RetinopathyRetinal Vein OcclusionWet Age-related Macular DegenerationWet Macular Degeneration

Phase 1

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO
TerminatedNCT03790852
Kodiak Sciences IncDiabetic Macular Edema, Retinal Vein Occlusion, Wet Age-related Macular Degeneration
Start: 2018-12-26End: 2022-06-09Updated: 2024-03-20

Phase 2

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
TerminatedNCT04049266
Kodiak Sciences IncWet Macular Degeneration
Start: 2019-10-08End: 2022-04-26Updated: 2024-07-18

Phase 3

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
CompletedNCT04592419
Kodiak Sciences IncMacular Edema, Retinal Vein Occlusion
Start: 2020-09-25End: 2023-01-19Updated: 2024-06-26
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
TerminatedNCT04603937
Kodiak Sciences IncDiabetic Macular Edema
Start: 2020-09-30End: 2023-08-31Updated: 2024-08-22
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
TerminatedNCT04611152
Kodiak Sciences IncDiabetic Macular Edema
Start: 2020-09-30End: 2023-08-31Updated: 2024-08-22
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
CompletedNCT04964089
Kodiak Sciences IncWet Age-related Macular Degeneration
Start: 2021-06-23End: 2023-04-06Updated: 2024-07-03
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
TerminatedNCT05066230
Kodiak Sciences IncNon-proliferative Diabetic Retinopathy
Start: 2021-09-07End: 2023-08-31Updated: 2024-09-05

Related Papers

Antibodies to watch in 2020.
2020-01-01328 citations